How to Get Rezdiffra (Resmetirom) in Ohio

Why Rezdiffra Matters for Ohio Patients with MASH

Rezdiffra (resmetirom) is the first drug the FDA approved specifically for MASH with liver fibrosis. Before its March 2024 approval, no pharmacotherapy carried a labeled indication for this condition, leaving an estimated 6, 8 million Americans with moderate to advanced fibrosis without a targeted treatment option [1]. Ohio ranks among the top 15 states for MASLD/MASH prevalence, driven in part by obesity rates that reached 36.4% among adults in the 2023 BRFSS survey [2].

The MAESTRO-NASH trial (N=966) demonstrated that resmetirom 100 mg achieved NASH resolution without worsening fibrosis in 25.9% of patients at 52 weeks, compared to 9.7% with placebo (P<0.001) [1]. A secondary endpoint showed fibrosis improvement by at least one stage in 24.2% of the 100 mg group versus 14.2% on placebo [1]. These numbers represent a meaningful clinical advance for a disease that previously progressed unchecked toward cirrhosis and liver transplant.

"Resmetirom is the first therapy to demonstrate both NASH resolution and fibrosis improvement in a phase 3 trial," noted the FDA's approval announcement for Rezdiffra [3]. Ohio clinicians now have a concrete pharmacologic tool to pair with lifestyle modifications for patients whose fibrosis staging warrants intervention.

Eligibility Criteria: Who Qualifies in Ohio

To receive a Rezdiffra prescription in Ohio, you must meet the FDA-labeled indication: adults with noncirrhotic MASH and moderate to advanced hepatic fibrosis (stages F2 or F3). This is not a weight-loss drug. It is not indicated for simple steatosis (fatty liver without inflammation) or for compensated or decompensated cirrhosis (F4).

Confirmation of fibrosis staging typically requires one of two pathways. Liver biopsy remains the reference standard and is preferred by most insurers during prior authorization review. Non-invasive testing, including vibration-controlled transient elastography (FibroScan) with a result between 8.0 and 13.9 kPa, or an Enhanced Liver Fibrosis (ELF) score above 9.8, may also support the diagnosis [4]. Ohio-based insurers vary in their acceptance of non-invasive markers alone, so clinicians should confirm payer-specific documentation requirements before submitting.

Patients with concurrent type 2 diabetes are eligible, and this subgroup represented roughly 60% of the MAESTRO-NASH cohort [1]. Ohio Medicaid specifically limits its current coverage pathway to patients carrying both a MASH and T2D diagnosis, a restriction that does not apply to most commercial plans.

Step-by-Step: Getting a Prescription in Ohio

The process from initial evaluation to first dose typically spans 3 to 6 weeks, depending on insurance response times and pharmacy logistics. Here is the clinical workflow.

Step 1: Diagnostic workup. Your provider orders baseline labs including a comprehensive metabolic panel (CMP), complete blood count (CBC), lipid panel, HbA1c, and liver function tests (ALT, AST, GGT, albumin, platelets). A FibroScan or liver biopsy confirms fibrosis stage. If you already have recent imaging or biopsy results (within 6 to 12 months), these may be sufficient.

Step 2: Prescriber evaluation. A hepatologist, gastroenterologist, endocrinologist, or primary care physician reviews your staging, rules out cirrhosis, and determines whether resmetirom 80 mg (for patients weighing <100 kg) or 100 mg (for patients ≥100 kg) is appropriate [3]. Ohio law permits MDs, DOs, NPs with a standard care arrangement, and PAs with a supervisory agreement to prescribe.

Step 3: Prior authorization submission. Your prescriber's office submits documentation to your insurer. Required materials almost always include the fibrosis staging report (biopsy pathology or elastography result), recent LFTs, and a letter of medical necessity. Average turnaround for Ohio commercial plans is 5, 15 business days.

Step 4: Pharmacy routing. Once approved, the prescription routes to a specialty pharmacy or an Ohio-licensed 503A compounding pharmacy. Madrigal's Rezdiffra Connect program can assist with identifying participating pharmacies and navigating copay support.

Step 5: Ongoing monitoring. After starting therapy, repeat LFTs at 3 months and every 6 months. Your provider should also reassess fibrosis status at 12 months to evaluate treatment response [3].

Telehealth Access for Resmetirom in Ohio

Ohio permits telehealth prescribing of resmetirom with no in-person visit requirement for the initial prescription, provided the prescriber establishes an adequate patient-provider relationship through a synchronous audio-video encounter [5]. This is significant for patients in rural Ohio counties where hepatology specialists are scarce. According to the AASLD workforce data, 73 of Ohio's 88 counties lack a practicing hepatologist [6].

Telehealth platforms that employ board-certified hepatologists or gastroenterologists can evaluate imaging results, review uploaded lab work, and issue an electronic prescription to an Ohio pharmacy. The Ohio State Medical Board updated its telemedicine rules in 2023 to align with post-pandemic standards, allowing controlled and non-controlled substance prescribing via telehealth when clinical criteria are met [5].

A practical note: even with telehealth, you will still need in-person access to a FibroScan device or biopsy facility. Many Ohio health systems, including Cleveland Clinic, Ohio State University Wexner Medical Center, and UC Health in Cincinnati, offer FibroScan as an outpatient procedure with results available same-day. Some patients complete the elastography locally and then have their telehealth hepatologist interpret the findings during a virtual follow-up.

Ohio Pharmacy and 503A Compounding Options

Rezdiffra is distributed through specialty pharmacy channels. Madrigal Pharmaceuticals uses a limited distribution network, meaning the drug is not available at standard retail pharmacies like CVS or Walgreens. Ohio patients typically receive their supply through one of the following channels.

Specialty pharmacies enrolled in the Rezdiffra distribution network handle the majority of prescriptions. These pharmacies coordinate with your insurer on prior authorization, manage copay assistance enrollment, and ship directly to your home or provider's office. Delivery within Ohio generally takes 3, 5 business days after insurance approval.

503A compounding pharmacies licensed in Ohio may compound resmetirom preparations under specific conditions. Ohio Board of Pharmacy regulations permit 503A pharmacies to compound patient-specific prescriptions when a prescriber determines that a commercially available product does not meet the patient's clinical needs [7]. This pathway is less common for resmetirom given the availability of manufactured tablets but may apply in cases requiring dose adjustments outside the standard 80 mg and 100 mg options.

Patients should verify that any 503A pharmacy they use holds a current Ohio Board of Pharmacy license and sources resmetirom API (active pharmaceutical ingredient) from an FDA-registered supplier. The Ohio Board of Pharmacy's licensee search tool can confirm a facility's active status.

Insurance and Cost Considerations in Ohio

The wholesale acquisition cost (WAC) for Rezdiffra is approximately $47,400 per year [8]. Out-of-pocket costs vary widely based on insurance type and plan design.

Commercial insurance: Most Ohio-based commercial plans, including those offered through Anthem, Medical Mutual, and UnitedHealthcare, classify Rezdiffra as a specialty tier drug requiring prior authorization. Copays after approval range from $0 to $150 per month when combined with Madrigal's copay assistance program, which caps out-of-pocket costs at $0 for eligible commercially insured patients during the initial launch period [8].

Ohio Medicaid: As of early 2026, Ohio Medicaid managed care plans cover Rezdiffra only for patients who carry both a MASH diagnosis and a type 2 diabetes diagnosis. Patients with MASH alone (without T2D) are currently excluded from Ohio Medicaid formularies. This limitation reflects the state's clinical criteria, not an FDA restriction. Advocacy groups, including the American Liver Foundation, have submitted comments urging broader state Medicaid coverage for MASH therapies [9].

Medicare Part D: Medicare covers Rezdiffra under Part D specialty tier with prior authorization. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, effective since 2025, limits maximum patient exposure for Medicare beneficiaries in Ohio [10].

"The out-of-pocket barrier for MASH patients is real, but the copay programs and Medicare cap changes have made access more feasible than many expected at launch," according to guidance from the American Association for the Study of Liver Diseases (AASLD) [9].

Prior Authorization: What Ohio Insurers Require

Prior authorization is required by virtually all Ohio payers. The documentation package typically includes the following.

Clinical documentation: Liver biopsy report showing NASH Activity Score (NAS) ≥4 with fibrosis stage F2 or F3, or a FibroScan result with liver stiffness measurement between 8.0 and 13.9 kPa plus elevated ALT. Some plans also accept the FIB-4 index above 1.3 as supporting (not standalone) evidence [4].

Lab results: Recent comprehensive metabolic panel, CBC, and lipid panel (typically within 90 days). Thyroid function tests (TSH, free T4) are also commonly requested because resmetirom is a thyroid hormone receptor beta (THR-β) agonist, and prescribers must document normal thyroid function at baseline [3].

Letter of medical necessity: A brief clinical narrative from the prescribing physician explaining the diagnosis, fibrosis staging method, treatment rationale, and why lifestyle modification alone has been insufficient. Ohio insurers do not universally require documented failure of lifestyle intervention for a specific duration, but a 6-month history of dietary counseling or structured weight management strengthens the submission.

Turnaround times: Ohio insurers must respond to prior authorization requests within 72 hours for urgent cases and 15 calendar days for standard requests under Ohio Revised Code § 3922.14. In practice, most Rezdiffra PAs are processed within 5, 10 business days for commercial plans and 7, 15 business days for Medicaid managed care.

Required Lab Monitoring on Resmetirom

The FDA label mandates specific laboratory monitoring for patients taking Rezdiffra [3]. Ohio prescribers should follow this schedule.

Before starting treatment: TSH, free T4, ALT, AST, total bilirubin, alkaline phosphatase, albumin, INR, CBC, and lipid panel. These establish baseline thyroid function (critical given the drug's THR-β agonist mechanism) and liver synthetic function to rule out occult cirrhosis.

At 3 months: Repeat LFTs (ALT, AST, total bilirubin). The FDA label warns that ALT elevations above 5× the upper limit of normal require treatment discontinuation [3]. In MAESTRO-NASH, ALT elevations above 3× ULN occurred in 3.8% of patients on resmetirom 100 mg versus 0.5% on placebo [1].

Every 6 months thereafter: LFTs and lipid panel. Resmetirom significantly reduces LDL cholesterol (a secondary finding from MAESTRO-NASH showed a 13.6% LDL reduction at 52 weeks versus a 0.1% increase on placebo) [1], so ongoing lipid monitoring helps clinicians adjust statin dosing if needed.

At 12 months: Repeat fibrosis assessment (FibroScan or biopsy) to evaluate treatment response. If no improvement in fibrosis stage or NAS score, the prescriber should reassess the risk-benefit balance of continued therapy.

Ohio's major academic liver centers, including Cleveland Clinic's Digestive Disease Institute and Ohio State's hepatology program, have built resmetirom monitoring protocols into their electronic health record order sets, reducing the chance of missed follow-up labs.

Resmetirom's Mechanism: Why It Works Differently

Resmetirom is a selective thyroid hormone receptor beta (THR-β) agonist. It does not activate THR-α, which controls heart rate and bone metabolism [11]. This selectivity is what separates it from older thyroid hormone analogs that caused cardiac side effects.

THR-β is expressed predominantly in the liver. When activated, it increases hepatic fatty acid oxidation and reduces lipogenesis, directly addressing the metabolic dysfunction that drives fat accumulation, inflammation, and fibrosis in MASH [11]. Think of it as pressing the accelerator on liver fat burning while releasing the brake on fat production.

In MAESTRO-NASH, resmetirom reduced hepatic fat content (measured by MRI-PDFF) by 45 to 50% at 52 weeks [1]. This fat reduction correlated with improvements in liver inflammation scores and, in roughly one quarter of patients, measurable fibrosis regression. The drug also lowered several atherogenic lipid markers: LDL-C by 13.6%, triglycerides by 20%, and lipoprotein(a) by approximately 30% [1]. These lipid effects may carry long-term cardiovascular benefit for MASH patients, who already face elevated cardiovascular mortality risk [12].

Side effects in MAESTRO-NASH were predominantly gastrointestinal. Diarrhea occurred in 27.0% of the 100 mg group versus 17.6% on placebo, and nausea in 21.7% versus 12.6% [1]. Most GI symptoms were mild to moderate and resolved within the first 12 weeks of treatment.

Transferring a Prescription to Ohio

If you have an existing resmetirom prescription from another state, transferring it to an Ohio pharmacy requires a few steps. Your out-of-state prescriber can authorize the transfer to an Ohio-licensed specialty pharmacy. Because Rezdiffra uses a limited distribution network, the receiving pharmacy must be enrolled in Madrigal's distribution program.

Ohio Board of Pharmacy rules permit prescription transfers for non-controlled legend drugs between licensed pharmacies [7]. Resmetirom is not a controlled substance, so the transfer process follows standard protocols. Your new Ohio-based prescriber (if you are switching providers) can also write a new prescription after reviewing your medical records, including the original fibrosis staging and recent labs.

For patients relocating to Ohio, the most efficient approach is to establish care with an Ohio hepatologist or gastroenterologist, have your records forwarded, and let the new provider issue a fresh prescription routed to an Ohio specialty pharmacy. This avoids potential delays associated with inter-state pharmacy transfers and ensures your new provider takes ownership of ongoing monitoring.